Enzo Biochem Introduced The Colonsentry Blood-Based Risk Stratification Test

Enzo Biochem, a molecular diagnostics company, has introduced the ColonSentry blood-based risk stratification test to assess a patient's risk of having colorectal cancer.

ColonSentry requires a small blood sample and utilizes RNA to measure the level of expression of seven specific genes.

Enzo president Barry Weiner said ColonSentry recently received New York State Department of Health approval.

"We also have, pending for New York State approval, our first assay based test on our new proprietary low cost and highly sensitive AmpiProbe nucleic acid amplification and detection technology platform," Weiner added.